Altace is a brand name of ramipril, approved by the FDA in the following formulation(s):
ALTACE (ramipril - capsule; oral)
Manufacturer: KING PHARMS
Approval date: January 28, 1991
Strength(s): 1.25MG [AB], 10MG [RLD][AB], 2.5MG [AB], 5MG [AB]
Has a generic version of Altace been approved?
A generic version of Altace has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Altace and have been approved by the FDA:
ramipril capsule; oral
Manufacturer: APOTEX
Approval date: June 20, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: AUROBINDO PHARMA LTD
Approval date: June 8, 2011
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: CIPLA
Approval date: August 7, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: DR REDDYS LABS LTD
Approval date: June 18, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: INVAGEN PHARMS
Approval date: June 18, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: LUPIN
Approval date: June 9, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: RANBAXY
Approval date: March 6, 2009
Strength(s): 10MG [AB], 5MG [AB]
Manufacturer: ROXANE
Approval date: June 18, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: SANDOZ
Approval date: June 18, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: TEVA PHARMS
Approval date: June 18, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: WATSON LABS
Approval date: October 24, 2005
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Manufacturer: ZYDUS PHARMS USA
Approval date: September 2, 2008
Strength(s): 1.25MG [AB], 10MG [AB], 2.5MG [AB], 5MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Altace. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
Patent 5,403,856
Issued: April 4, 1995
Inventor(s): Henning; Rainer & Urbach; Hansjorg & Teetz; Volker & Geiger; Rolf & Scholkens; Bernward
Assignee(s): Hoechst Aktiengesellschaft
The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.Patent expiration dates:
- April 4, 2012✓
- April 4, 2012
Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
Patent 7,368,469
Issued: May 6, 2008
Inventor(s): Schölkens; Bernward & Bender; Norbert & Rangoonwala; Badrudin & Dagenais; Gilles & Gerstein; Hertzel & Yusuf; Salim
Assignee(s): Sanofi-Aventis Deutschland GmbH
Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.Patent expiration dates:
- August 30, 2020✓
- August 30, 2020
See also...
- Altace Consumer Information (Drugs.com)
- Altace Consumer Information (Wolters Kluwer)
- Altace Capsules Consumer Information (Wolters Kluwer)
- Altace Consumer Information (Cerner Multum)
- Altace Advanced Consumer Information (Micromedex)
- Altace AHFS DI Monographs (ASHP)
- Ramipril Consumer Information (Drugs.com)
- Ramipril Consumer Information (Wolters Kluwer)
- Ramipril Capsules Consumer Information (Wolters Kluwer)
- Ramipril Consumer Information (Cerner Multum)
- Ramipril Advanced Consumer Information (Micromedex)
- Ramipril AHFS DI Monographs (ASHP)
No comments:
Post a Comment